Markets:

Overview

News

Currencies

International

Treasuries

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

129.46 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 05, 2023

Via Benzinga

Meta Platforms To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday ↗

June 05, 2023

BMO Capital boosted the price target for Equity Residential (NYSE: EQR) from $60 to $64. BMO Capital analyst John Kim upgraded the stock from Underperform to Market Perform. Equity Residential shares...

Via Benzinga

This Biotech Could Soon Go Parabolic, But Should You Buy It? ↗

June 04, 2023

Its situation is neither as good nor as bad as it might seem at first glance.

Via The Motley Fool

Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's Future ↗

May 23, 2023

Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) after it received FDA approval for its Ayvakit (avapritinib) as the first, only treatment for

Via Benzinga

FDA OKs Blueprint Medicines' Blood Disorder Drug As First Treatment For SM Patients ↗

May 23, 2023

The U.S.

Via Benzinga

Analyst Expectations for Blueprint Medicines's Future ↗

May 23, 2023

Via Benzinga

Blueprint Medicines's Return On Capital Employed Overview ↗

May 15, 2023

Via Benzinga

Analyst Ratings for Blueprint Medicines ↗

May 05, 2023

Via Benzinga

Where Blueprint Medicines Stands With Analysts ↗

April 19, 2023

Via Benzinga

16 Analysts Have This to Say About Blueprint Medicines ↗

March 30, 2023

Via Benzinga

FDA Removes Partial Clinical Hold From Blueprint Medicines' Cancer Study ↗

March 29, 2023

Via Benzinga

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Where Blueprint Medicines Stands With Analysts ↗

February 27, 2023

Via Benzinga

Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients ↗

February 27, 2023

Via Benzinga

Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines ↗

February 23, 2023

Via Benzinga

Earnings Scheduled For February 16, 2023 ↗

February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...

Via Benzinga

Earnings Preview For Blueprint Medicines ↗

February 15, 2023

Via Benzinga

Analyst Ratings for Blueprint Medicines ↗

January 23, 2023

Via Benzinga

Where Blueprint Medicines Stands With Analysts ↗

December 12, 2022

Via Benzinga

FDA Slaps Partial Clinical Hold On Blueprint Medicines' Early-Stage Solid Tumor Study ↗

February 10, 2023

Via Benzinga

Blueprint Medicines's Return On Capital Employed Overview ↗

November 07, 2022

According to data from Benzinga Pro, during Q3, Blueprint Medicines's (NASDAQ:BPMC) reported sales totaled $65.98 million. Despite a 16.62% increase in earnings, the company posted a loss of $133.16...

Via Benzinga

Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake ↗

November 02, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗

November 02, 2022

Upgrades

Via Benzinga

9 Analysts Have This to Say About Blueprint Medicines ↗

November 02, 2022

Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:

Via Benzinga

Recap: Blueprint Medicines Q3 Earnings ↗

November 01, 2022

Blueprint Medicines (NASDAQ:BPMC) reported its Q3 earnings results on Tuesday, November 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

Where Blueprint Medicines Stands With Analysts ↗

September 09, 2022

Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter:

Via Benzinga

Uber To Rally Around 82%? Here Are 5 Other Price Target Changes For Wednesday ↗

November 02, 2022

Needham raised Uber Technologies, Inc. (NYSE: UBER) price target from $52 to $54. Needham analyst Bernie McTernan maintained the stock with a Buy rating. Uber shares fell 0.3% to $29.65 in pre-market...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022 ↗

September 14, 2022

Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low...

Via Benzinga

What 14 Analyst Ratings Have To Say About Blueprint Medicines ↗

August 22, 2022

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

Headline News about Blueprint Medicines Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today